Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience.
Adult
Age Factors
Antibodies, Monoclonal, Humanized
/ therapeutic use
Biological Products
/ therapeutic use
Cohort Studies
Drug Substitution
Female
Humans
Italy
Male
Middle Aged
Patient Safety
Prognosis
Psoriasis
/ drug therapy
Quality of Life
Retrospective Studies
Risk Assessment
Severity of Illness Index
Sex Factors
Treatment Outcome
Ustekinumab
/ therapeutic use
Young Adult
Psoriasis
Secukinumab
Switch
Ustekinumab
Journal
Dermatology (Basel, Switzerland)
ISSN: 1421-9832
Titre abrégé: Dermatology
Pays: Switzerland
ID NLM: 9203244
Informations de publication
Date de publication:
2019
2019
Historique:
received:
24
09
2018
accepted:
25
01
2019
pubmed:
1
4
2019
medline:
18
12
2019
entrez:
1
4
2019
Statut:
ppublish
Résumé
Switching between biologics is commonly performed for the management of plaque psoriasis. However, no evidence about switching from secukinumab to ustekinumab has been reported. This retrospective observational multicenter study aimed to describe efficacy and safety of ustekinumab in secukinumab nonresponder patients. A total of 21 patients unresponsive to secukinumab were treated with ustekinumab for a mean period of 53.3 weeks. Ustekinumab was effective in reducing disease severity, with significant improvements of both psoriasis area severity index (PASI) and dermatology quality of life index (DLQI) scores. PASI score improvements of 31.8, 44, 77.8, 80.3, 80.5, and 89.6%, at week 4, 12, 24, 36, 48, and above 60 weeks, respectively, were detected (p < 0.05), achieving PASI 50, 75, and > 90 responses in 93.8, 87.5, and 50% of patients at week 48. Four patients withdrew from ustekinumab treatment because of inefficacy, and failure of multiple biologic agents (> 2) seemed to affect ustekinumab drug survival. No serious adverse events (AEs) were reported while 38.1% of patients experienced mild AEs. Ustekinumab was safe and effective in treating patients unresponsive to secukinumab.
Sections du résumé
BACKGROUND
BACKGROUND
Switching between biologics is commonly performed for the management of plaque psoriasis. However, no evidence about switching from secukinumab to ustekinumab has been reported.
METHODS
METHODS
This retrospective observational multicenter study aimed to describe efficacy and safety of ustekinumab in secukinumab nonresponder patients.
RESULTS
RESULTS
A total of 21 patients unresponsive to secukinumab were treated with ustekinumab for a mean period of 53.3 weeks. Ustekinumab was effective in reducing disease severity, with significant improvements of both psoriasis area severity index (PASI) and dermatology quality of life index (DLQI) scores. PASI score improvements of 31.8, 44, 77.8, 80.3, 80.5, and 89.6%, at week 4, 12, 24, 36, 48, and above 60 weeks, respectively, were detected (p < 0.05), achieving PASI 50, 75, and > 90 responses in 93.8, 87.5, and 50% of patients at week 48. Four patients withdrew from ustekinumab treatment because of inefficacy, and failure of multiple biologic agents (> 2) seemed to affect ustekinumab drug survival. No serious adverse events (AEs) were reported while 38.1% of patients experienced mild AEs.
CONCLUSION
CONCLUSIONS
Ustekinumab was safe and effective in treating patients unresponsive to secukinumab.
Identifiants
pubmed: 30928971
pii: 000497274
doi: 10.1159/000497274
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Biological Products
0
secukinumab
DLG4EML025
Ustekinumab
FU77B4U5Z0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
213-218Informations de copyright
© 2019 S. Karger AG, Basel.